SomaLogic announces first early-access site for its SOMAscan assay proteomics platform

Colorado-based biomarker discovery and clinical diagnostics company SomaLogic, Inc., has announced that the Perelman School of Medicine at the University of Pennsylvania is the first biomedical research center that will offer researchers on-site access to the SOMAscan assay, a proteomics platform. The assay will be performed at Penn’s Institute for Translational Medicine and Therapeutics (ITMAT), under the leadership of Daniel J. Rader, MD, associate director of ITMAT and chair of the Department of Genetics, and Stephen Master, MD, PhD, assistant professor of Pathology and Laboratory Medicine and director of ITMAT’s Translational Core Laboratory. It is expected that the assay will be fully functional at Penn by midsummer.

“We anticipate announcing several additional centers over the next few months, and are carefully evaluating additional requests from many different research centers for SOMAscan placement at their respective institutions.”

“We are delighted that our first partner in bringing our powerful technology to more researchers is the University of Pennsylvania,” says Byron Hewett, CEO of SomaLogic. “The leadership of Dr. Rader and Dr. Master, together with the University’s reputation and skills in applying cutting-edge biotechnology tools to critical biomedical questions, will help ensure that this first non-SomaLogic center for our SOMAscan assay will be successful.”

SomaLogic's SOMAscan proteomic assay identifies and quantifies 1,129 proteins across a wide range of concentrations in small volumes of multiple biological sample types. Its uses include protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. Until now, it has only been offered as a service through SomaLogic at its laboratories in Boulder, CO.

The SOMAscan placement is the first under an agreement between Agilent Technologies and SomaLogic to expand access to the SOMAscan platform in research centers in addition to the commercial SOMAscan service offered directly by SomaLogic throughout the U.S. and internationally. Read more about the SOMAscan assay.